LDFR
ESPR

Lehman & Derafelo Financial Resources’s Esperion Therapeutics ESPR Stock Holding History

Lehman & Derafelo Financial Resources’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,400
Closed -$52K – 243
2020
Q3 		$52K Hold
1,400
– – 0.02% 172
2020
Q2 		$72K Buy
+1,400
New +$58.6K 0.03% 149

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Lehman & Derafelo Financial Resources's ESPR Position: Q4 2020 in Review

Lehman & Derafelo Financial Resources sold out of Esperion Therapeutics (ESPR) in Q4 2020, closing a stake of 1,400 shares — an estimated $52K sold.

Lehman & Derafelo Financial Resources first reported a position in ESPR in Q2 2020 and held it in 2 quarters. The position peaked at $72K in Q2 2020. 157 funds tracked by Wall St. Rank hold ESPR as of Q4 2020.

  • Lehman & Derafelo Financial Resources reported no remaining Esperion Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Lehman & Derafelo Financial Resources sold 1,400 Esperion Therapeutics shares in Q4 2020, an estimated $52K.
  • Lehman & Derafelo Financial Resources first reported a position in Esperion Therapeutics in Q2 2020 and held it in 2 quarters.
  • Lehman & Derafelo Financial Resources's Esperion Therapeutics position peaked at $72K in Q2 2020.
  • 157 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2020.

Based on Lehman & Derafelo Financial Resources's 13F filing for Q4 2020, filed 20 Jan 2021.